Psychopharmacologia

, Volume 9, Issue 4, pp 307–319 | Cite as

Zur Beeinflussung der Nahrungsaufnahme durch Psychopharmaka

  • Klaus Opitz
  • Ayotunde Akinlaja
Originalarbeiten
Received:

Summary

The effects of 16 psychotropic drugs on food intake and body weight were studied in female Wistar rats under carefully controlled conditions. After 3 days of placebo treatment the drugs were administered orally 1 hr prior to a 12-hours-per-day feeding period for at least 3 further days. Normal daily feed consumption averaged 6.11 g/100 g BW. Haloperidol, reserpine, chlorpromazine, chlorprothixene, promethazine, azacyclonol, imipramine, and amitriptyline in appropriate doses all reduced both food intake and body weight, but there were marked differences in activity. Small amounts of chlorpromazine may even stimulate feeding behaviour. Chlorpromazine sulfoxide was without influence. The central stimulant Tradon® evoked anorexia whereas only short-lasting anorexigenic effects if any were observed following the administration of either 2-diethylamino-4-oxo-5-phenyl-oxazoline or pipradol. On the other hand chlordiazepoxide, phenobarbital, and to some extent oxazepam caused the animals to increase their feed consumption and to gain weight. The results are discussed with regard to clinical reports of appetite and weight changes due to psychotropic drugs.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arnold, O. H., u. G. Foitl: Die Behandlung der endogenen Depression mit Amitriptylin. Wien. med. Wschr. 111, 272–274 (1961).PubMedGoogle Scholar
  2. Bowes, H. A.: The role of Librium in an out-patient psychiatric setting. Dis. nerv. Syst. 21, 20–22 (1960).Google Scholar
  3. Breitner, C.: Drug therapy in obsessional states and other psychiatric problems. Dis. nerv. Syst. 21, 31–35 (1960).PubMedGoogle Scholar
  4. Brown, B. B., and H. W. Werner: Pharmacological studies on a new central stimulant, α-(2-piperidyl)benzhydrol hydrochloride (MRD-108). J. Pharmacol. exp. Ther. 110, 180–187 (1954).PubMedGoogle Scholar
  5. Chimenes, H.: Intérêt de l'imipramine dans le traitement des obésités. Presse méd. 72, 1131–1132 (1964).Google Scholar
  6. Franke, E. A.: Erfahrungen mit 5-Phenyl-2-imino-4-oxo-oxazolidin bei psychisch Kranken. Med. Klin. 54, 2080–2082 (1959).PubMedGoogle Scholar
  7. Grossie, J., and C. W. Turner: Normal feed consumption of female Sprague-Dawley-Rolfsmeyer rats. Proc. Soc. exp. Biol. (N.Y.) 110, 748–749 (1962).Google Scholar
  8. Hippius, H.: Komplikationen der Langzeit-Therapie mit Psychopharmaka. Landarzt 41, 933–940 (1965).Google Scholar
  9. Jakob, I.: Erfahrungen mit Tofranil bei endogenen und reaktiven Depressionen. Wien. med. Wschr. 110, 259–260 (1960).PubMedGoogle Scholar
  10. Janssen, P. A. J.: Vergleichende pharmakologische Daten über sechs basische 4′-Fluorobutyrophenon-Derivate. Arzneimittel-Forsch. 11, 819–824 (1961).Google Scholar
  11. —, C. J. E. Niemegeers, and K. H. L. Schellekens: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I: Neuroleptic activity spectra for rats. Arzneimittel-Forsch. 15, 104–117 (1965).Google Scholar
  12. Jost, F., u. E. Weber: Kurz- und Langzeitbehandlungen der depressiven Syndrome mit Laroxyl (Amitriptylin). Praxis 51, 650–656 (1962).PubMedGoogle Scholar
  13. Jünemann, H. J., H. J. Krüger u. H. Schwarz: Beitrag zur klinischen Therapie mit Librium. Med. Welt (Berl.) 1961 I, 1094–1100.Google Scholar
  14. Karczmar, A. G., and J. H. Howard jr.: Anorexigenic action of methylphenidate (Ritalin) and pipradol (Meratran). Proc. Soc. exp. Biol. (N.Y.) 102, 163–167 (1959).Google Scholar
  15. Kinross-Wright, J., I. M. Cohen, and J. A. Knight: The management of neurotic and psychotic states with Ro-5-0690 (Librium). Dis. nerv. Syst. 21, 23–26 (1960).Google Scholar
  16. Kuhn, E.: Appetite stimulating effect of barbiturate-induced therapeutic sleep. Experientia (Basel) 15, 77–79 (1959).Google Scholar
  17. Kuhn, R.: The treatment of depressive states with G 22355 (Imipramine hydrochloride). Amer. J. Psychiat. 115, 459–464 (1958/59).Google Scholar
  18. Löffler-Schnebli, M.: Librium und seine Nebenwirkungen in der Geriatrie. Schweiz. med. Wschr. 91, 1320–1322 (1961).PubMedGoogle Scholar
  19. Mayer, J.: Glucostatic mechanism of regulation of food intake. New Engl. J. Med. 249, 13–16 (1953).PubMedGoogle Scholar
  20. McGovern, J. P., K. Ozkaragoz, G. Barkin, T. Haywood, T. McElhenney, and A. E. Hensel jr.: Studies of chlordiazepoxide in various allergic diseases. Ann. Allergy 18, 1193–1199 (1960).PubMedGoogle Scholar
  21. Opitz, K.: Wirkungen psychotroper Substanzen auf den Stoffwechsel. Arzneimittel-Forsch. 12, 333–340; 525–531; 618–626 (1962).Google Scholar
  22. —: Spezialkäfig für die Messung der Nahrungsaufnahme von Ratten. Arzneimittel-Forsch. 15, 190 (1965a).Google Scholar
  23. —: Einfluß von Psychopharmaka auf die nichtveresterten Fettsäuren im Blutplasma. Experientia (Basel) 21, 462–464 (1965b).Google Scholar
  24. Randall, L. O.: Pharmacology of Methaminodiazepoxide. Dis. nerv. Syst. 21, 7–10 (1960).PubMedGoogle Scholar
  25. —, W. Schallek, C. Scheckel, R. E. Bagdon u. J. Rieder: Zur Pharmakologie von Mogadon, einem Schlafmittel mit neuartigem Wirkungsmechanismus. Schweiz. med. Wschr. 95, 334–337 (1965).PubMedGoogle Scholar
  26. Reynolds, R. W., and H. J. Carlisle: The effect of chlorpromazine on food intake in the albino rat. J. comp. physiol. Psychol. 54, 354–356 (1961).PubMedGoogle Scholar
  27. Ross, S., and M. V. Rhoades: Chlorpromazine effects on food intake in the rat. Psychol. Rep. 9, 639–642 (1961).Google Scholar
  28. Sarwer-Foner, G. J., H. Grauer, J. Mackay, and E. K. Koranyi: Depressive states and drugs. A study of the use of imipramine Tofranil in open psychiatric settings. Med. Serv. J. Can. 15, 359–382 (1959).PubMedGoogle Scholar
  29. Schmidt, H. jr., and W. G. van Meter: Chlorpromazine depression of food intake in the albino rat. J. comp. physiol. Psychol. 51, 29–31 (1958).Google Scholar
  30. Schmidt, L.: 5-Phenyl-2-imino-4-oxo-oxazolidin — ein zentral erregender Stoff. Arzneimittel-Forsch. 6, 423–426 (1956).Google Scholar
  31. Soulairac, A., et M. L. Soulairac: Étude expérimentale de l'action de la chlorpromazine sur le comportement alimentaire et l'activité spontanée du rat. Encéphale 1956, 927–931.Google Scholar
  32. — —: Action de la réserpine, de la sérotonine et de l'iproniazide sur le comportement alimentaire du rat. C.R. Soc. Biol. (Paris) 154, 510–513 (1960).Google Scholar
  33. Spengler, J., u. P. Waser: Der Einfluß verschiedener Pharmaka auf den Futterkonsum von Albino-Ratten im akuten Versuch. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 237, 171–185 (1959).Google Scholar
  34. Spranger, J.: Therapie der kindlichen Fettsucht. Päd. Praxis 3, 580–584 (1964).Google Scholar
  35. Stoller, A.: Tofranil—a new anti-depressant drug. Med. J. Aust. 1960, 412–414.Google Scholar
  36. Thalmann, R.: Depressionsbehandlung mit einem neuen Antidepressivum Laroxyl. Praxis 51, 671–676 (1962).PubMedGoogle Scholar
  37. Tobin, J. M., and N. D. C. Lewis: New psychotherapeutic agent, chlordiazepoxide. J. Amer. med. Ass. 174, 1242–1249 (1960).Google Scholar
  38. Wagensommer, J.: Therapeutisch unerwünschte Wirkungen der Neuroleptika. Dissertation, Med. Akad. Düsseldorf 1963.Google Scholar
  39. —: Therapeutisch unerwünschte Wirkungen der Thymoleptika. Fortschr. Neurol. Psychiat. 32, 497–512 (1964).Google Scholar
  40. Waller, M. B., and P. F. Waller: Effects of chlorpromazine on appetitive and aversive components of a multiple schedule. J. exp. Anal. Behav. 5, 259–264 (1962).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1966

Authors and Affiliations

  • Klaus Opitz
    • 1
  • Ayotunde Akinlaja
    • 1
  1. 1.Pharmakologisches Institut der Universität MünsterWestf.

Personalised recommendations